Please login to the form below
Ocrevus
This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.
Roche’s Ocrevus shows promise as a subcutaneous injection in phase 3 MS trial
The Ocrevus subcutaneous injection was shown to be non-inferior to the IV, as measured by pharmacokinetics (levels in the blood) over 12 weeks. ... The subcutaneous injection was also comparable in controlling MRI lesion activity in the brain over 12
Latest news
-
Roche shares new positive Ocrevus data for MS patients
The CONSONANCE trial showed treatment with Ocrevus resulted in a majority of patients experiencing no disease progression. ... For 75% of patients diagnosed with SPMS and PPMS treated with Ocrevus, they showed no evidence of progression (NEP) after one
-
Biogen reveals new data for MS therapies Tysabri and Vumerity
treatment. They found that in people receiving Tysabri treatment or Roche’s Ocrevus (ocrelizumab) with baseline impairment, statistically significant improvements were observed in ten of 12 and eight of 12 ... The adjusted annualised rate of
-
Roche’s Ocrevus shows significant benefit in early-stage MS patients
The early-stage data bolsters Ocrevus’ claim in the crowded MS market, particularly against Novartis’ Kesimpta (ofatumumab). ... Both Kesimpta and Ocrevus selectively target the immune system’s CD20-positive B cells that damage nerve tissue and
-
Novartis gains EU approval for relapsing MS drug Kesimpta
In particular, both Kesimpta and Ocrevus selectively target the immune system’s CD20-positive B cells that damage nerve tissue and cause disease progression. ... Unlike Kesimpta and Ocrevus, which target CD20-positive B cells, Ponvory inhibits S1P1
-
J&J’s MS drug ponesimod receives approval in the US
As well as the newer therapies, a range of blockbuster drugs are already available for MS, including Biogen’s Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab).
More from news
Approximately 23 fully matching, plus 38 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
To succeed, it will have to differentiate from its main direct competitor, the anti-CD20 monoclonal antibody Ocrevus, which has the first-to-market advantage, has labelled indications covering 95% of ... Even if bettering Ocrevus appears unlikely, the
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn
- Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
- UK-India research project trialling easy-to-use UTI test to support fight against AMR
- Cancer Research UK and Guardant collaborate to advance cancer detection and treatment
- Give the gift of positive change
- Apple Vision Pro: challenges and opportunities for pharma
No results were found
PMHub
Springer Nature
Did you know that we publish over 3,000 journals, and that over 1,000 of those are clinical science journals? Promote...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
